Publishing date: 28 July 2022
In this eLearning module, Vlad Ratziu outlines the pathophysiology of NASH, and its links to related comorbidities, as well as the progressive nature of the disease and the increased risk for patients to develop potential serious clinical outcomes.
When you have completed this activity you will be asked to fill in a short evaluation survey. Your feedback helps us to give you the best learning experience.
In support of improving patient care, this activity is accredited by North American Center for Continuing Medical Education (NACCME) for 0.25 AMA PRA Category 1 Credit(s)™. Should you wish to claim credits for this activity, please select “yes” in the question below and download your certificate. Should you simply wish to provide us with valuable feedback, please select “no” in the question below and submit your feedback.
Login or create a free account to get started
Login
Register
Learning objectives
Following completion of this activity, you will be able to:
- Identify patients at high risk for developing NASH
- Explain the best approach to the management of patients with NASH
- Discuss emergent therapies for the treatment of NASH
Faculty
Vlad Ratziu
Sorbonne Université, Paris, France
Vlad Ratziu is a Professor of Hepatology at Sorbonne University, and performs his hospital work at the Pitié-Salpêtrière Hospital and the Institute for Cardiometabolism and Nutrition (ICAN) in Paris, France. Professor Ratziu received his medical training at Paris Descartes University; he then completed a 2-year postdoctoral fellowship at the Liver Center at the University of California, San Francisco, CA, USA, and went on to earn a doctoral degree from Paris Diderot University for his work on the pathophysiology of viral and metabolic liver fibrosis.
Professor Ratziu’s main research interests are in the field of non-alcoholic fatty liver disease (NAFLD); the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He coordinated or participated in several therapeutic trials in NASH. He was also involved in different European financed FP7, Horizon 2020 and Innovative Medicines Initiative 2 consortia. He is a member of the organising committee of the NASH–TAG meetings. He is a Co-Editor for the Journal of Hepatology and an associate editor for Clinical Liver Disease. He has published more than 330 articles in top-tier specialty journals.
Disclosures
Consulting – Novo Nordisk
Accreditation
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates AMA PRA Category 1 Credit™ for the following activities:
- Completion of 15-minute patient case study: 0.25 AMA PRA Category 1 Credit™
Expiration date: 28th July 2023 - Completion of 15-minute eLearning module: 0.25 AMA PRA Category 1 Credit™
Expiration date: 28th July 2023 - Completion of 20-minute video module: 0.25 AMA PRA Category 1 Credit™
Expiration date: 1st September 2023 - Completion of all components listed above and the opening/closing videos: 1.0 AMA PRA Category 1 Credit™
How to claim your credits
To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.
Planning Committee
In addition to the expert faculty, NACCME and Springer Healthcare IME planners and staff include Kristin Kolack, Rachel Goddard, James Hutton, and Alba Ruzafa. The Planning Committee have no financial relationships to disclose.
Funding
This activity is supported by an educational grant from NOVO NORDISK A/S.
